Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 61 AL 75

Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease

O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, Kehoe PG, Guyatt G, Molloy DW.

J Alzheimers Dis. 2014;40(3):595-603. doi: 10.3233/JAD-131694.

Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral

Rush T, Buisson A.

Cell Tissue Res. 2014 May;356(2):279-86. doi: 10.1007/s00441-013-1789-1. Epub 2014 Feb 5.

How plausible is a link between HSV-1 infection and Alzheimer's disease?

Agostini S, Clerici M, Mancuso R.

Expert Rev Anti Infect Ther. 2014 Mar;12(3):275-8. doi: 10.1586/14787210.2014.887442. Epub 2014 Feb 6.

Arginine metabolising enzymes as targets against Alzheimers' disease

Whiteley CG.

Neurochem Int. 2014 Feb;67:23-31. doi: 10.1016/j.neuint.2014.01.013. Epub 2014 Feb 4.

Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease

Bennett DA, Yu L, De Jager PL.

Biochem Pharmacol. 2014 Apr 15;88(4):617-30. doi: 10.1016/j.bcp.2014.01.037. Epub 2014 Feb 6.

Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

Ponnayyan Sulochana S, Sharma K, Mullangi R, Sukumaran SK.

Biomed Chromatogr. 2014 Nov;28(11):1431-90. doi: 10.1002/bmc.3116. Epub 2014 Feb 11.

Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines

Davtyan H, Bacon A, Petrushina I, Zagorski K, Cribbs DH, Ghochikyan A, Agadjanyan MG.

Hum Vaccin Immunother. 2014;10(5):1248-55. doi: 10.4161/hv.27882. Epub 2014 Feb 13.

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

Talbot K, Wang HY.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S12-25. doi: 10.1016/j.jalz.2013.12.007.

Vaccination against Alzheimer disease: an update on future strategies

Fettelschoss A, Zabel F, Bachmann MF.

Hum Vaccin Immunother. 2014;10(4):847-51. doi: 10.4161/hv.28183. Epub 2014 Feb 17.

Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group.

Phytomedicine. 2014 May 15;21(6):888-92. doi: 10.1016/j.phymed.2014.01.003. Epub 2014 Feb 16.

D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease

Kumar J, Sim V.

Prion. 2014 Jan-Feb;8(1):119-24. doi: 10.4161/pri.28220.

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan R, Vassar R.

Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17.

The role of inflammasome in Alzheimer's disease

Liu L, Chan C.

Ageing Res Rev. 2014 May;15:6-15. doi: 10.1016/j.arr.2013.12.007. Epub 2014 Feb 19.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD005380. doi: 10.1002/14651858.CD005380.pub5.

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: a comprehensive review of evidences

Saravanaraman P, Chinnadurai RK, Boopathy R.

Rev Neurosci. 2014;25(2):231-46. doi: 10.1515/revneuro-2013-0056.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias